Company News

Share this article:

Abbott opened a nutrition product manufacturing facility in Singapore, in order to meet increasing regional demand for its pediatric products, including Similac, according to company statement. The facility represents the company's largest nutrition investment to date, at $300 million. According to Abbott, the facility will serve up to one million Asian infants and children each year.

 

FDA halted the review of all NDA's received from a Ranbaxy Laboratories plant in India, after discovering falsified data. In a letter to Ranbaxy, CDER director Janet Woodcock said the findings “indicate a pattern and practice of submitting untrue statements of material fact and other wrongful conduct, which raise significant questions regarding the reliability of the data and information contained in applications (pending and approved) that [Ranbaxy] has filed with the agency and which contain data developed at the Ranbaxy Laboratories, Paonta Sahib site.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies